Cargando…
A novel oncolytic adenovirus based on simian adenovirus serotype 24
Among the oncolytic virotherapy, an emerging treatment for tumor, adenoviruses are widely used at present in preclinical and clinical trials. Traditionally, oncolytic adenoviruses were developed based on the human adenovirus serotype 5 (AdHu5). However, AdHu5 has the drawbacks of preexisting anti-Ad...
Autores principales: | Cheng, Tao, Song, Yufeng, Zhang, Yan, Zhang, Chao, Yin, Jieyun, Chi, Yudan, Zhou, Dongming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432303/ https://www.ncbi.nlm.nih.gov/pubmed/28460470 http://dx.doi.org/10.18632/oncotarget.15845 |
Ejemplares similares
-
Development of a novel simian adenovirus 24 based vaccine vector
por: Abbink, P, et al.
Publicado: (2012) -
Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35
por: Ono, Ryosuke, et al.
Publicado: (2021) -
Simian adenoviruses as vaccine vectors
por: Morris, Susan J, et al.
Publicado: (2016) -
Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5
por: Nguyen, Tien V., et al.
Publicado: (2017) -
Oncolytic Adenoviruses in Gastrointestinal Cancers
por: Yokoda, Raquel T., et al.
Publicado: (2018)